To the full analysis
Avalo Therapeutics stock: growth
AVTXAvalo Therapeutics reported $59K in revenue for fiscal 2025, down 86.6% on the prior year.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−2.6%
per year from 2012 to 2025, per share −36.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | −61.2% | no data | −2.6% |
| Revenue per share | −88.9% | no data | −36.4% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $82.76K | −$10.49M | −$9.3M |
| 2013 | $0 | −$13.05M | −$11.51M |
| 2014 | $0 | −$16.06M | −$15.54M |
| 2015 | $0 | −$10.49M | −$10.18M |
| 2016 | $1.15M | −$16.47M | −$14.61M |
| 2017 | $27.81M | $11.87M | $12.5M |
| 2018 | $18.33M | −$40.05M | −$3.69M |
| 2019 | $6.75M | −$16.07M | −$19.4M |
| 2020 | $6.7M | −$63.5M | −$40.6M |
| 2021 | $5.4M | −$84.38M | −$71.01M |
| 2022 | $18.05M | −$41.66M | −$26.85M |
| 2023 | $1.92M | −$31.54M | −$30.84M |
| 2024 | $441K | −$35.13M | −$49.06M |
| 2025 | $59K | −$78.26M | −$51.46M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.